Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan : Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America..

BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant.

METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed.

RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged ≥65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months.

CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:75

Enthalten in:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 75(2022), 11 vom: 30. Nov., Seite 1971-1979

Sprache:

Englisch

Beteiligte Personen:

Maeda, Haruka [VerfasserIn]
Saito, Nobuo [VerfasserIn]
Igarashi, Ataru [VerfasserIn]
Ishida, Masayuki [VerfasserIn]
Suami, Kazuya [VerfasserIn]
Yagiuchi, Ai [VerfasserIn]
Kimura, Yuya [VerfasserIn]
Komino, Masaru [VerfasserIn]
Arai, Hiromi [VerfasserIn]
Morikawa, Toru [VerfasserIn]
Motohashi, Iori [VerfasserIn]
Miyazawa, Rei [VerfasserIn]
Moriyama, Tetsu [VerfasserIn]
Kamura, Hiroshi [VerfasserIn]
Terada, Mayumi [VerfasserIn]
Kuwamitsu, Osamu [VerfasserIn]
Hayakawa, Tomoichiro [VerfasserIn]
Sando, Eiichiro [VerfasserIn]
Ohara, Yasuji [VerfasserIn]
Teshigahara, Osamu [VerfasserIn]
Suzuki, Motoi [VerfasserIn]
Morimoto, Konosuke [VerfasserIn]

Links:

Volltext

Themen:

BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Delta
Japan
Journal Article
Multicenter Study
RNA, Messenger
Research Support, Non-U.S. Gov't
SARS-CoV-2
Vaccine effectiveness

Anmerkungen:

Date Completed 02.12.2022

Date Revised 15.01.2023

published: Print

Citation Status MEDLINE

doi:

10.1093/cid/ciac292

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM339675039